Jian-Guo Zhou
周建国


github.com/JianGuoZhou3
ORCID Scholar

Research summary

I am a Deputy Chief Physician (Doctoral Supervisor) of Zunyi Medical University. My research is dedicated to enhancing the efficacy of cancer immunotherapy and radiation/chemotherapy while minimizing adverse effects.

Together with Dr. Shixiang Wang, I lead the OncoHarmony Network1, a dynamic collaborative platform aimed at advancing the frontier of cancer immunotherapy. This network unites diverse teams from leading universities and research institutions, focusing on the exploration, mining, and integration of multi-omics data in cancer research. By fostering synergy among experts, the OncoHarmony Network seeks to create a comprehensive resource hub and cutting-edge tools to unravel the complexities of tumor-immune interactions, accelerating breakthroughs in cancer therapy development.

Research positions

year what
2017 Primary Investigator, Department of Oncology, Second Affiliated hospital of Zunyi Medical University2

Medical positions

year what
2024 Deputy Chief Physician, Doctoral Supervisor, Oncology, Second Affiliated hospital of Zunyi Medical University3
2019 Attending Physician, Master Thesis Supervisor, Oncology, Second Affiliated hospital of Zunyi Medical University4
2017 Residency, Oncology, Second Affiliated hospital of Zunyi Medical University5

Education

year what
2019 Dr. rer. biol. hum (PhD) in Radiation Oncology [summa cum laude], Friedrich-Alexander-Universität Erlangen-Nürnberg6
Supervisor: Prof. Udo Gaipl7
2014 M.S. in Thoracic Oncology, Zunyi Medical University8
Supervisor: Prof. Hu Ma9
2009 M.D. in Clinical Medicine, Northwest Minzu University
Supervisor: Prof. Siwu Fu

Committee Memberships

year what
2025 Member, Committee of Neoplastic Supportive-care (CONS), Chinese Anti-Cancer Association (CACA)
2025 Member, Expert Committee of Melanoma, Chinese Society of Clinical Oncology (CSCO)
2024 Member, Youth Expert Committee, West China Society of Therapeutic and Radiation Oncology (CSWOG-RTOG)
2023 Member, Committee of Thoracic Oncology Precision Treatment, China Primary Health Care Foundation (CPHCF)
2023 Member, Committee of Application of Foods for Special Medical Purposes, China Nutrition and Health Food Association (CNHFA)

Service

year what
2025 Editorial Board Member of BJC reports
2023 Editorial Board Member of BMC Medicine
2023 Associate Editor of European Journal of Medical Research
2022 Associate Editor of Frontiers in Immunology
2022 Associate Editor of Frontiers in Oncology
2022 Associate Editor Technology in Cancer Reasech & Treatment
2018 Journal Referees: Nature Medicine, Innovation, BMC Medicine, Seminars in Cancer Biology, cancer commnuications, Journal of Experimental & Clinical Cancer Research, Cell Proliferation, Frontiers in Immunology, Frontiers in OncologyGynecologic Oncology, iMeta, Strahlentherapie und Onkologie, Clinical and Translational Medicine, Nucleosides Nucleotides & Nucleic Acids, BMC Gastroenterology, Immunopharmacology And Immunotoxicology, Cancer Investigation, Oncoimmuology, Chinese Medical Journal, Journal of Cancer Research and Clinical Oncology, JCO Clinical Cancer Informatics, Ibrain, Journal of Proteome Research, Innovation Medicine, Genes & Diseases, Cancer Gene Therapy, Cellular Signaling, Molecular Oncology, Journal of Obstetrics and Gynaecology, Cancer Immunology Immunotherapy, Journal of the National Cancer Center, Journal for ImmunoTherapy of Cancer, Oncoimmunology, International Journal of Cancer, Clinical Nutrition, Computational and Structural Biotechnology Journal et al.
2018 Section Editor of Cancer Control
2022 Guest Editor of Therapeutic Advances in Med Oncol: Genomic Biomarkers in Cancer Immunotherapy

Major grants and funding

year what
2024 Zunyi Medical University (ZYSE-2023-02)10 (¥ 2100k),
Title: Future Science and Technology Elite Talent Cultivation Project
2021 Lian Yun Gang Shi Hui Lan Public Foundation (Grant No. HL-HS2020-92)11 (¥ 50k),
Title: Based on machine learning methods to explore the role of multi-omics as predictor for NSCLC treated with third-generation EGFR-TKIs
2021 National Natural Science Foundation of China12 (¥ 340k),
Title: Long noncoding RNA MALAT1 promotes Invasion and Metastasis via the FGF23 / β-catenin pathway-mediated EMT in Uterine Sarcoma
2019 Research Programs of Health Commission Foundation of Guizhou Province, gzwjkj2019-1-07313 (¥ 20k),
Title: Identification and validation of Immune related Prognostic Models in Oral Squamous Cell Carcinoma
2018 the Special Key Laboratory of Oral Diseases Research, Higher Education Institution in Guizhou Province, No.05] (¥ 20k),
Title: Identification and validation of a Prognostic Signature in Oral Cancer

Awards & honours

year what
2024 2024 Guizhou Pharmaceutical Science and Techonology Award (Second Class, 1/6), Guizhou
2022 Chinese Government Award for Outstanding Self-financed Students Abroad (2021-A404), Germany
2021 Guizhou Medical Science and Techonology Award (Second Class, 1/6), Guizhou
2020 KSMO 2020 Young Investigator Award, Seoul
2018 Guizhou Medical Science and Techonology Award (Third Class, 4/5), Guizhou
2019 ESMO Asia 2019 Merit Award, Singapore
CSCO Young Oncologist Award (35 under 35), Beijing
2018 ESMO Asia 2018 Merit Award, Singapore

Publications

Journal articles (fully reviewed, # for co-first, † for corresponding)

year number citation
2024 J64 Single-cell RNA-seq reveals FGF12 as a prognostic biomarker in low-grade endometrial stromal sarcoma
Y. Miao#, M. Dong#, Q. Zhou#, J. Thiel, N. Li, Y. Cai, D. Yuan, H. Wang, S. Jin, H. Yang, J. Wang, B. Frey, U. S Gaipl, H. Ma†, J. Zhou†
Frontiers in Immunology (JCR Q1, CAS Q2, IF: 5.7)
J63 Efficacy of radiotherapy combined with atezolizumab or docetaxel in patients with previously treated NSCLC
J. Xu#, H. Wang#, C. Zhang, S. Jin, X. Chen, F. Tan, B. Frey, M. Hecht, J. Sun, U. S Gaipl†, H. Ma†, J. Zhou†
iScience (JCR Q1, CAS Q2, IF: 4.6)
J62 Facilitating integrative and personalized oncology omics analysis with UCSCXenaShiny
S. Li#, Y. Peng, M. Chen, Y. Zhao, Y. Xiong, J. Li, P. Luo, H. Wang, F. Zhao, Q. Zhao, Y. Cui, S. Chen†, J. Zhou†, S. Wang†
Communications Biology (JCR Q1, CAS Q1, IF: 5.2)
J61 A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung Cancer
C. Chen#, M. Chen, Y. Bai, Y. Li, J. Peng, B. Yao, J. Feng, J. Zhou†, H.
Technology in Cancer Research and Treatment (JCR Q4, CAS Q4, IF: 2.7)
J60 FGF23 is a potential prognostic biomarker in uterine sarcoma
L. Yang#, Y. Cai#, Y. Wang, Y. Huang, C. Zhang, H. Ma†, J. Zhou†
Technology in Cancer Research and Treatment (JCR Q4, CAS Q4, IF: 2.7)
J59 Effects of serial radon spa therapy on pain and peripheral immune status in patients suffering from musculoskeletal disorders– results from a prospective, randomized, placebo-controlled trial.
A. Donaubauer#, I. Becker, G. Klein, R. E. Voll, L. Weikl, M. Klieser, S. Barzangi, J. Zhou, R. Fietkau, U. S. Gaipl†, B. Frey
Frontiers in Immunology (JCR Q1, CAS Q2, IF: 7.3)
J58 Machine learning based on blood test biomarkers predicts fast progression in advanced NSCLC patients treated with immunotherapy
J. Zhou#, J. Yang#, H. Wang, A. Hang-Heng Wong, F. Tan, X. Chen, s. he, G. Shen, Y. Wang, B. Frey, R. Fietkau, M. Hecht, W. Zhong, H. Ma†, G. Udo†
BMJ Oncology
J57 Positive response to trastuzumab deruxtecan in a patient with HER2-mutant NSCLC after multiple lines therapy, including T-DM1: a case report
J. Xu#, B. He, Y. Wang, M. Wu, Y. Lu, Z. Su, S. Liu, F. Yin, J. Zhou†, W. Hu†
Frontiers in Oncology (JCR Q2, CAS Q3, IF: 3.5)
J56 Machine Learning-assisted immunophenotyping of peripheral blood identifies innate immune cells as best predictor of response to induction chemo-immunotherapy in head and neck squamous cell carcinoma - knowledge obtained from the CheckRad-CD8 trial
M. Hecht#†, B. Frey#, U. S Gaipl#, X. Tianyu, M. Eckstein, A. Donaubauer, G. Klautke, T. Illmer, M. Fleischmann, S. Laban, M. G Hautmann, B. Tamaskovics, T. B Brunner, I. Becker, J. Zhou, A. Hartmann, R. Fietkau, H. Iro, M. Döllinger, A. Gostian, A. M Kist
Neoplasia (JCR Q2, CAS Q2, IF: 4.80)
J55 TCCIA: a comprehensive resource for exploring CircRNA in cancer immunotherapy
S. Wang#, Y. Xiong#, Y. Zhang#, H. Wang, M. Chen, J. Li, P. Luo, Y. Luo, M. Hecht, B. Frey, U. Gaipl, X. Li†, Q. Zhao†, H. Ma†, J. Zhou†
Journal for ImmunoTherapy of Cancer (JCR Q1, CAS Q1, IF: 10.9)
2023 J54 Identification of immunological bioprocesses involved in peri-implantitis using weighted gene co-expression network analysis
L. Chen#, S. Jin#, Q. Lu, J. Zhou, J. Liu, X. Guan, H. Xia†, H. He†
Journal of Periodontology (JCR Q1, CAS Q2 TOP, IF: 4.30)
J53 Identification and characterization of circular RNAs as novel putative biomarkers to predict anti-PD-1 monotherapy response in metastatic melanoma patients - Knowledge from two independent international studies
J. Zhou#, R. Liang#, H. Wang, S. Jin, W. Hu, B. Frey, R. Fietkau, M. Hecht, H. Ma†, U. S Gaipl†
Neoplasia (JCR Q2, CAS Q2, IF: 4.80)
2022 J52 Identification of an endogenous retroviral signature to predict anti-PD1 response in advanced clear cell renal cell carcinoma: an integrated analysis of three clinical trials
J. Zhou#, Y. Zeng#, H. Wang, S. Jin, Y. Wang, S. He, B. Frey, R. Fietkau, M. Hecht, H. Ma†, W. Zhang†, U. S Gaipl†
Therapeutic Advances in Medical Oncology (JCR Q2, CAS Q2, IF: 4.90)
J51 Definition of a new blood cell count score for early survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of four multicenter clinical trials
J. Zhou#, A. Hang-Heng Wong#, H. Wang#, S. Jin, F. Tan, Y. Chen, S. He, G. Shen, B. Frey, R. Fietkau, M. Hecht, S. R Carr, R. Wang, B. Shen, D. S Schrump†, H. Ma†, U. S Gaipl†
Frontiers in Immunology (JCR Q1, CAS Q2 TOP, IF: 8.79)
J50 Editorial: Uncovering Drug Resistance During Cancer Therapy
H. Wang†, R. Wang, J. Zhou, W. Hou, A. Hang-Heng Wong†
Frontiers in Genetics (JCR Q2, CAS Q3, IF: 3.70)
J49 Elucidation of the Application of Blood Test Biomarkers to Predict Immune-Related Adverse Events in Atezolizumab-Treated NSCLC Patients Using Machine Learning Methods
J. Zhou†, A. Hang-Heng Wong#, H. Wang, F. Tan, X. Chen, S. Jin, S. He, G. Shen, Y. Wang, B. Frey, R. Fietkau, M. Hecht, H. Ma†, U. S Gaipl†
Frontiers in Immunology (JCR Q1, CAS Q2 TOP, IF: 8.79)
J48 Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practic
S. Ma#, X. Bai#, X. Guo #, L. Liu#, L. Xiao, Y. Lin, J. Tan, X. Cai, Y. Wen, H. Ma, Q J. Fu, M. Leng, Y. Zhang, L. Long, Z. Guo, D. Wu†, J. Zhou†, Z. Dong†
BMC Medicine (JCR Q1, CAS Q1, IF: 11.81)
J47 Editorial: The Clinical Application of Neoantigens
J. Zhou†, Z. Ding, H. Shi, M. Cheng
Frontiers in Immunology (JCR Q1, CAS Q2 TOP, IF: 8.79)
J46 Low-Dose Radiotherapy Leads to a Systemic Anti-Inflammatory Shift in the Pre-Clinical K/BxN Serum Transfer Model and Reduces Osteoarthritic Pain in Patients
T. Weissmann#, M. Rückert, J. Zhou, M. Seeling, S. Lettmaier, A. Donaubauer, F. Nimmerjahn, O. J Ott, M. Hecht, F. Putz, R. Fietkau, B. Frey, U. S Gaipl†, L. Deloch
Frontiers in Immunology (JCR Q1, CAS Q2 TOP, IF: 8.79)
2021 J45 Screening and validation of a novel T stage-lymph node ratio classification for operable colon cancer
J. Pei#, R. Zhang#, N. Zhang#, Y. Zeng, Z. Sun, S. Ma, J. Zhou, X. Li, J. Fan, J. Zhu, M. Abe, Z. Mei, G. Shi, C. Zhang†
Annals of Translational Medicine (JCR Q3, CAS Q4, IF: 3.62)
J44 Establishment and Validation of a Prognostic Immune Signature in Neuroblastoma
Y. Yu#, Y. Zeng#, X. Xia, J. Zhou, F. Cao†
Cancer Control (JCR Q3, CAS Q4, IF: 2.60)
J43 Identification of 15 lncRNAs Signature for Predicting Survival Benefit of Advanced Melanoma Patients Treated with Anti-PD-1 Monotherapy
J. Zhou#, B. Liang#, J. Liu#, S. Jin, S. He, B. Frey, N. Gu, R. Fietkau, M. Hecht, H. Ma†, U. S Gaipl†
Cells (JCR Q2, CAS Q2, IF: 6.00)
J42 Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer
S. Semrau†, A. Gostian, M. Traxdorf, M. Eckstein, S. Rutzner, J. von der Grün, T. Illmer, M. Hautmann, G. Klautke, S. Laban, T. Brunner, B. Tamaskovics, B. Frey, J. Zhou, C. Geppert, A. Hartmann, P. Balermpas, W. Budach, U. Gaipl, H. Iro, R. Fietkau, M. Hecht
Cancers (Basel) (JCR Q2, CAS Q2, IF: 5.20)
J41 Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors
L. Maria Griewing#, C. Schweizer, P. Schubert, S. Rutzner, M. Eckstein, B. Frey, M. Haderlein, T. Weissmann, S. Semrau, A. Gostian, S. K. Müller, M. Traxdorf, H. Iro, J. Zhou, U. S. Gaipl, R. Fietkau, M. Hecht†
BMC Cancer (JCR Q2, CAS Q2, IF: 3.80)
J40 Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors
J. Zhou#, A. Donaubauer#, B. Frey, I. Becker, S. Rutzner, M. Eckstein, R. Sun, H. Ma, P. Schubert, C. Schweizer, R. Fietkau, E. Deutsch, U. Gaipl†, M. Hecht†
Journal for ImmunoTherapy of Cancer (JCR Q1, CAS Q1, IF: 13.75)
J39 Editorial: The Role of ncRNAs in Solid Tumors Prognosis: From Laboratory to Clinical Utility
J. Zhou†, Z. Huang, O. Slaby, A. Navarro
Frontiers in Oncology (JCR Q2, CAS Q2, IF: 5.74)
2020 J38 Development of an miRNA-Array-Based Diagnostic Signature for Periodontitis
S. Jin#, J. Zhou, X. Guan, G. Bai, J. Liu†, L. Chen†
Frontiers in Genetics (JCR Q2, CAS Q3, IF: 3.70)
J37 Prospective Evaluation of All-lesion Versus Single-lesion Radiotherapy in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors
P. Schubert†, S. Rutzner, M. Eckstein, B. Frey, C. Schweizer, M. Haderlein, S. Lettmaier, S. Semrau, A. Gostian, J. Zhou, U. S Gaipl, R. Fietkau, M. Hecht
Frontiers in Oncology (JCR Q2, CAS Q3, IF: 4.70)
J36 Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy
C. Schweizer†, P. Schubert, S. Rutzner, M. Eckstein, M. Haderlein, S. Lettmaier, S. Semrau, A. Gostian, B. Frey, U. S Gaipl, J. Zhou, R. Fietkau, M. Hecht
European Journal of Cancer (JCR Q1, CAS Q1, IF: 8.40)
J35 Low Dose Radiation Therapy, Particularly with 0.5 Gy, Improves Pain in Degenerative Joint Disease of the Fingers: Results of a Retrospective Analysis
A. Donaubauer#, J. Zhou#, O. J Ott, F. Putz, R. Fietkau, L. Keilholz, U. S Gaipl, B. Frey, T. Weissmann†
International Journal of Molecular Sciences (JCR Q1, CAS Q2, IF: 5.60)
J34 Co-expression gene modules involved in cisplatin-induced peripheral neuropathy according to sensitivity, status, and severity
R. Zhou#, C. Chen#, S. Jin, J. Li, Z. Xu, L. Ye†, J. Zhou†
Journal of the Peripheral Nervous System (JCR Q2, CAS Q3, IF: 3.80)
J33 Development and Validation of a Gene Signature for Prediction of Relapse in Stage I Testicular Germ Cell Tumors
J. Zhou#, J. Yang#, S. Jin#, S. Xiao, L. Shi, T. Zhang, H. Ma†, U. S Gaipl†
Frontiers in Oncology (JCR Q2, CAS Q3, IF: 4.70)
J32 Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials
J. Zhou#, L. Huang#, S. Jin#, C. Xu, B. Frey, H. Ma†, U. S Gaipl†
ESMO Open (JCR Q1, CAS Q2, IF: 7.30)
2019 J31 Influence of marital status on overall survival in patients with ovarian serous carcinoma: finding from the surveillance epidemiology and end results (SEER) database
P. Luo#, J. Zhou†, S. Jin, M. Qing, H. Ma†
Journal of Ovarian Research (JCR Q1, CAS Q3, IF: 4.00)
J30 Development and Validation of an RNA-Seq-Based Prognostic Signature in Neuroblastoma
J. Zhou#, B. Liang#, S. Jin#, H. Liao, G. Du, L. Cheng, H. Ma†, U. S Gaipl†
Frontiers in Oncology (JCR Q2, CAS Q3, IF: 4.70)
J29 Identification of a RNA-seq-based signature to improve prognostics for uterine sarcoma
J. Zhou††, H. Zhao#, S. Jin#, X. Tian, H. Ma†
Gynecologic Oncology (JCR Q1, CAS Q2, IF: 4.70)
J28 Identification of novel key lncRNAs involved in periodontitis by weighted gene co-expression network analysis
S. Jin#, R. Zhou#, X. Guan#, J. Zhou†, J. Liu†
Journal of Periodontal Research (JCR Q2, CAS Q3, IF: 3.50)
J27 An overview on the methodological and reporting quality of dose-response meta-analysis on cancer prevention
C. Xu#, Y. Liu, C. Zhang, J. S W Kwong, J. Zhou, L. Ge, J. Huang †, T. Liu †
Journal of Cancer Research and Clinical Oncology (JCR Q2, CAS Q3, IF: 3.66)
J26 Development and Validation of a Prognostic Signature for Malignant Pleural Mesothelioma
J. Zhou#†, H. Zhong#, J. Zhang, S. Jin, R. Roud, H. Ma†
Frontiers in Oncology (JCR Q2, CAS Q3, IF: 4.70)
2018 J25 Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial
J. Zhou#†, N. Zhou#, Q. Zhang, Y. Feng, H. Zhou†
Trials (JCR Q3, CAS Q4, IF: 2.50)
J24 Molecular epidemiology of lung cancer in Iran: implications for drug development and cancer prevention
Z. Fathi#, N. L Syn, J. Zhou, R. Roudi†
Journal of Human Genetics (JCR Q2, CAS Q3, IF: 3.55)
2017 J23 Opioid-Induced Constipation Relief From Fixed-Ratio Combination Prolonged-Release Oxycodone/Naloxone Compared With Oxycodone and Morphine for Chronic Nonmalignant Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
L. Huang#, J. Zhou#, Y. Zhang, F. Wang, Y. Wang, D. Liu, X. Li, S. Lv, S. Jin, Y. Bai, H. Ma†
Journal of Pain and Symptom Management (JCR Q1, CAS Q2, IF: 4.70)
J22 Diagnostic accuracy of PCR for detecting ALK gene rearrangement in NSCLC patients: A systematic review and meta-analysis
X. Zhang#, J. Zhou#, H. Wu, H. Ma†, Z. Jiang†
Oncotarget (JCR Q2, CAS Q3, IF: 5.17)
J21 Systematic review and meta-analysis of the efficacy of serum neuron-specific enolase for early small cell lung cancer screening
L. Huang#, J. Zhou#, W. Yao#, X. Tian, S. Lv, T. Zhang, S. Jin, Y. Bai and Hu Ma†
Oncotarget (JCR Q2, CAS Q3, IF: 5.17)
J20 Concurrent chemo-radiotherapy with S-1 as an alternative therapy for elderly Chinese patients with non-metastatic esophageal squamous cancer: evidence based on a systematic review and meta-analysis
G. Song#, X. Tian#, X. Liu#, H. Chen, J. Zhou, W. Bian, W. Chen†
Oncotarget (JCR Q2, CAS Q3, IF: 5.17)
J19 Meta-Analysis of Serum Gastrin-Releasing Peptide Precursor as a Biomarker for Diagnosis of Small Cell Lung Cancer
S. Ping Lv#, Y. Wang, L. Huang, F. Wang, J. Guo Zhou, H. Ma†
Asian Pacific Journal of Cancer Prevention
2016 J18 Meta-analysis comparing chewing gum versus standard postoperative care after colorectal resection
G. Song#, Y. Deng#, Y. Jin#, J. Zhou, X. Tian†
Oncotarget (JCR Q2, CAS Q3, IF: 5.17)
J17 Efficacy of D5F3 IHC for detecting ALK gene rearrangement in NSCLC patients: a systematic review and meta-analysis
H. Ma#, W. Yao#, L. Huang#, S. Jin, D. Liu, Y. Liu, X. Tian, J. Tian, J. Zhou†
Oncotarget (JCR Q2, CAS Q3, IF: 5.17)
J16 Laparoscopic cholecystectomy for acute cholecystitis: early or delayed?: Evidence from a systematic review of discordant meta-analyses
G. Song#, W. Bian#, X. Zeng#, J. Zhou, Y. Luo, X. Tian†
Medicine (Baltimore) (JCR Q3, CAS Q4, IF: 1.60)
J15 The role of neoadjuvant chemotherapy for resectable colorectal liver metastases: a systematic review and meta-analysis
W. Liu#, J. Zhou, Y. Sun, L. Zhang, B. Xing†
Oncotarget (JCR Q2, CAS Q3, IF: 5.17)
J14 The Adverse Events of Oxycodone in Cancer-Related Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
H. Ma#, Y. Liu#, L. Huang#, X. Zeng, S. Jin, G. Yue, X. Tian, J. Zhou†
Medicine (Baltimore) (JCR Q3, CAS Q4, IF: 1.60)
J13 Moxibustion is an Alternative in Treating Knee Osteoarthritis: The Evidence From Systematic Review and Meta-Analysis
G. Song#, X. Tian#, Y. Jin#, Y. Deng, H. Zhang, X. Pang†, J. Zhou†
Medicine (Baltimore) (JCR Q3, CAS Q4, IF: 2.13)
2015 J12 The Efficacy of Erlotinib Versus Conventional Chemotherapy for Advanced Nonsmall-Cell Lung Cancer: A PRISMA-Compliant Systematic Review With Meta-Regression and Meta-Analysis
H. Ma#, W. Yao#, L. Huang#, S. Jin, D. Liu, Y. Liu, X. Tian, J. Tian, J. Zhou†
Medicine (Baltimore) (JCR Q3, CAS Q4, IF: 1.60)
J11 Reply to comments on the relationship between green tea consumption and the risk of endometrial cancer
Q. Zhou#, H. Li, J. Zhou, T. Wu†
Archives of Gynecology and Obstetrics (JCR Q3, CAS Q3, IF: 2.60)
J10 Hepatic Resection Improved the Long-Term Survival of Patients with BCLC Stage B Hepatocellular Carcinoma: a Letter to Response
W. Liu#, J. Zhou, B. Xing†
Journal of Gastrointestinal Surgery (JCR Q2, CAS Q3, IF: 3.20)
J09 Number of parity and the risk of gallbladder cancer: a systematic review and dose-response meta-analysis of observational studies
P. Guo†, C. Xu#, Q. Zhou#, J. Zhou, J. Zhao, Z. Si, C. Shen, C. Feng†
Archives of Gynecology and Obstetrics (JCR Q3, CAS Q3, IF: 2.60)
J08 The Risk of Neutropenia and Leukopenia in Advanced Non-Small Cell Lung Cancer Patients Treated With Erlotinib: A Prisma-Compliant Systematic Review and Meta-Analysis
J. Zhou#, X. Tian#, L. Cheng#, Q. Zhou, Y. Liu, Y. Zhang, Y. Bai†, H. Ma†
Medicine (Baltimore) (JCR Q3, CAS Q4, IF: 1.60)
J07 Coffee consumption and risk of endometrial cancer: a dose-response meta-analysis of prospective cohort studies
Q. Zhou#, M. Luo, H. Li, M. Li, J. Zhou†
scientific reports (JCR Q2, CAS Q2, IF: 5.23)
J05 Role of Enteral Immunonutrition in Patients Undergoing Surgery for Gastric Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
G. Song#, X. Tian†, H. Liang#, L. Yi#, J. Zhou, Z. Zeng, T. Shuai, Y. Ou, L. Zhang, Y. Wang
Medicine (Baltimore) (JCR Q3, CAS Q4, IF: 1.60)
J06 Oral Motor Intervention Improved the Oral Feeding in Preterm Infants: Evidence Based on a Meta-Analysis With Trial Sequential Analysis
X. Tian#, L. Yi#, L. Zhang#, J. Zhou, L. Ma, Y. Ou, T. Shuai, Z. Zeng, G. Song†
Medicine (Baltimore) (JCR Q3, CAS Q4, IF: 1.60)
J04 Immunonutrition Support for Patients Undergoing Surgery for Gastrointestinal Malignancy: Preoperative, Postoperative, or Perioperative? A Bayesian Network Meta-Analysis of Randomized Controlled Trials
G. Song#, X. Tian†, L. Zhang#, Y. Ou#, L. Yi, T. Shuai, J. Zhou, Z. Zeng, H. Yang
Medicine (Baltimore) (JCR Q3, CAS Q4, IF: 1.60)
J03 Green tea, black tea consumption and risk of endometrial cancer: a systematic review and meta-analysis
Q. Zhou#, H. Li#, J. Zhou#, Y. Ma, T. Wu†, H. Ma†
Archives of Gynecology and Obstetrics (JCR Q3, CAS Q3, IF: 2.60)
J02 Treatment of Adults With Treatment-Resistant Depression: Electroconvulsive Therapy Plus Antidepressant or Electroconvulsive Therapy Alone? Evidence From an Indirect Comparison Meta-Analysis
G. Song#, X. Tian†, T. Shuai#, L. Yi, Z. Zeng, S. Liu, J. Zhou, Y. Wang
Medicine (Baltimore) (JCR Q3, CAS Q4, IF: 1.60)
2014 J01 Treatment on advanced NSCLC: platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone? A systematic review and meta-analysis of randomised controlled trials
J. Zhou†, X. Tian#, X. Wang#, J. Tian, Y. Wang, F. Wang, Y. Zhang, H. Ma†
Medical Oncology (JCR Q3, CAS Q4, IF: 3.40)

The journal impact factors mentioned above are derived from the maximum values in the history of journal impact factors. Journal impact factors, Chinese Academy of Sciences (CAS) categorization, and JCR categorization were all uniformly updated on 2023.11.02. For future publications that are included, I will update them selectively and will no longer perform uniform updates on all publications.

Preprints (not reviewed, † for co-first, * for corresponding)

year number citation

Cited by

Talks

year number what
2021 T5 ESMO Immuno-Oncology Congress 2021[Geneva, Switzerland]
3O - Identification of an endogenous retroviral signature to predict PD-1 blockade response in advanced clear cell renal cell carcinoma: Integrated analysis of 3 clinical trials
2020 T4 ESMO ASIA VIRTUAL CONGRESS 2020[Singapore, Republic of Singapore]
Development of a flow cytometry-based whole-blood prognostic immune signature in metastatic cancer patients treated with immune checkpoint inhibitors
T3 KSMO 2020 VIRTUAL (13th Annual Meeting & 2020 International Conference; The Korean Society of Medical Oncology; 8th International FACO Conference) [SEOUL, KOREA]
Identification of nine lncRNAs signature for predicting survival benefit of melanoma patients treated with immune checkpoint inhibitors
2019 T2 ESMO ASIA CONGRESS 2019[Singapore, Republic of Singapore]
Olanzapine combined with 5-HT3 RA plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in cancer patients: A systematic review and meta-analysis of randomized controlled trials
T1 EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY 2019 (14TH Meeting) [ LYON, FRANCE]
Development and Validation of a RNA-Seq Based Prognostic Signature in Neuroblastoma

Poster presentations

year number what
2018 P3 ESMO Asia 2018 Congress
372P Identification and validation of a prognostic signature in malignant pleural mesothelioma
2023 P1 SITC 2023
189 Systematic evaluation of transcriptomic molecular features in advanced renal clear cell carcinoma treated with immunotherapy
P2 SITC 2023
46 Efficacy of atezolizumab and docetaxel in patients with HER2-positive non-small cell lung cancer: a pooled post hoc of the OAK and POPLAR trials

Teaching experience

year what
2022 International Academic Exchange, basic course for doctoral students, Zunyi Medical University
2022 Introduction to Clinical Research, Clinical Medicine Nanshan Class, Zunyi Medical University

  1. https://github.com/OncoHarmony-Network↩︎

  2. https://www.zy2yy.cn/↩︎

  3. https://www.zy2yy.cn/↩︎

  4. https://www.zy2yy.cn/↩︎

  5. https://www.zy2yy.cn/↩︎

  6. https://www.fau.de/↩︎

  7. https://www.strahlenklinik.uk-erlangen.de↩︎

  8. https://www.zmu.edu.cn/↩︎

  9. https://www.zy2yy.cn/↩︎

  10. https://www.zmu.edu.cn/↩︎

  11. http://www.huilangongyi.org.cn/↩︎

  12. https://www.nsfc.gov.cn/↩︎

  13. https://wjw.guizhou.gov.cn/↩︎